Author:
Lee David Y.,Huynh Kelly T.,Teng Annabelle,Lau Briana J.,Vitug Sarah,Lee Ji-Hey,Stern Stacey L.,Foshag Leland J.,Faries Mark B.
Funder
Dr. Miriam & Sheldon G. Adelson Medical Research Foundation (Boston, MA)
John Wayne Cancer Institute Auxiliary
Borstein Family Foundation
George W. Ogden
John E. Connor
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.
2. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912–8.
3. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302–11; discussion 311–3.
4. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16(6):2253–60.
5. Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248(3):378–86.